摘要
目的分析利拉鲁肽联合二甲双胍治疗糖尿病合并肥胖症的效果。方法选取2022年1月至2023年1月辽宁省健康产业集团铁煤总医院内分泌科收治的70例糖尿病合并肥胖症患者作为研究对象,按照随机数字表法分为常规组(35例)与研究组(35例),常规组采用单一二甲双胍治疗方法,研究组采用利拉鲁肽联合二甲双胍治疗方法。比较两组患者的不良反应发生情况、血糖水平、体重指数(BMI)、炎症因子水平以及肠道菌群水平等指标。结果研究组的不良反应发生情况低于常规组,差异有统计学意义(P<0.05);研究组的血糖水平与BMI均低于常规组,差异有统计学意义(P<0.05);研究组的炎症因子水平均低于常规组,差异有统计学意义(P<0.05);研究组的双歧杆菌、拟杆菌高于常规组,肠杆菌、肠球菌低于常规组,差异有统计学意义(P<0.05)。结论对于糖尿病合并肥胖症患者应采用利拉鲁肽联合二甲双胍治疗,这种治疗方式可以改善患者肠道菌群水平、血糖水平以及BMI,降低患者炎症因子水平与不良反应发生率,应用效果十分显著。
Objective To analyze the effect of Liraglutide combined with Metformin in the treatment of diabetes combined with obesity.Methods From January 2022 to January 2023,70 patients with diabetes combined with obesity admitted to the Department of Endocrinology of Liaoning Health Industry Group Iron Coal General Hospital were selected as research subjects.According to random number table method,they were divided into conventional group(35 cases)and study group(35 cases).The conventional group was treated with Metformin alone,the study group was treated with Liraglutide combined with Metformin.Adverse reactions,blood glucose levels,body mass index(BMI),inflammatory factors and intestinal flora levels were compared between the two groups.Results The incidence of adverse reactions in the study group was lower than that in the conventional group,the difference was statistically significant(P<0.05).The blood glucose level and BMI of the study group were lower than those of the conventional group,and the differences were statistically significant(P<0.05).The levels of inflammatory factors in the study group were lower than those in the conventional group,and the differences were statistically significant(P<0.05).The bifidobacteria and bacteroides in the study group were higher than those in the conventional group,and the enterobacteria and enterococcus were lower than those in the conventional group,with statistical significances(P<0.05).Conclusion Liraglutide combined with Metformin should be used for the treatment of diabetes combined with obesity.This treatment can improve the level of intestinal flora,blood sugar and BMI of patients,reduce the level of inflammatory factors and the incidence of adverse reactions in patients,and the application effect is very significant.
作者
张琳琳
ZHANG Linlin(Department of Endocrinology,Liaoning Health Industry Group Iron Coal General Hospital,Liaoning Province,Tieling112700,China)
出处
《中国当代医药》
CAS
2023年第35期93-96,共4页
China Modern Medicine
